{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-002781","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2026-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.239766+00:00","generated_at":"2026-05-15T06:46:40.093617+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Sunshine Biopharma reports FY 2025 revenue $36.3M (+4.1% YoY), net loss $5.98M","bullets":["Revenue $36.31M vs $34.87M in 2024; gross profit $12.26M up from $10.67M.","Net loss widened to $5.98M from $5.13M, including $1.75M non-cash impairment charge.","Launched 9 new generic drugs in 2025, portfolio now 71 products; 12 more planned in 2026.","Raised $2.46M gross via registered direct offering to expand sales operations.","Cost-reduction initiatives expected to cut G&A by $2M-$3M in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-002781","json":"https://secwatch.observer/filing/0001683168-26-002781.json","markdown":"https://secwatch.observer/filing/0001683168-26-002781.md","text":"https://secwatch.observer/filing/0001683168-26-002781.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316826002781/0001683168-26-002781-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316826002781/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:46:40.093617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"db609ecd9fb89d0f05b3a6b57c3059703e7c6b7c","claim":"Sunshine Biopharma Inc. reported the year ended December 31, 2025 results: revenue $36.3 million.","evidence_excerpt":"specific reference in such filing. --- EX-99.1 (PRESS RELEASE) --- EX-99.1 2 sunshine_ex9901.htm PRESS RELEASE Exhibit 99.1 Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year FORT LAUDERDALE, FL / ACCESSWIRE / April 6, 2026 — Sunshine Biopharma Inc. (NASDAQ: SBFM) (“Sunshine Biopharma” or the “Company”), a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316826002781/0001683168-26-002781-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Revenue","value":"$36.3 million"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}